Jean-Baptiste Alberge

Has grant

Institut Gustave Roussy
Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Bridge grant

Open Date: 2021-01-01

Close Date: 2021-01-01

Grant: Close

Postdoctoral fellowship

Open Date: 2021-01-01

Close Date: 2022-01-01

Grant: Close

Mapping the hydroxymethylome in Multiple Myeloma

Open Date: 2017-01-01

Close Date: 2020-01-01

Articles (23)

Year:

2026

Year:

2026

The development of targeted therapy for patients with multiple myeloma (MM) is hampered by the low frequency of actionable genetic abnormalities. Gain or amplification of chromosome 1q (1q+) is the most frequent arm-level copy number gain in patients with MM and is associated with higher risk of progression and death despite recent therapeutic advances. Thus, developing targeted therapy for patients with MM with 1q+ stands to benefit a large portion of patients in need of more effective management. Here, we used large-scale dependency screens and drug screens to systematically characterize the therapeutic vulnerabilities of MM with 1q+ and displayed increased sensitivity to myeloid cell leukemia-1 (MCL1) and phosphatidyl inositol 3-kinase (PI3K) inhibitors. Using single-cell RNA sequencing, we compared subclones with and without 1q+ within the same patient tumors and demonstrated that 1q+ is associated with higher levels of MCL1 and the PI3K pathway. Furthermore, by isolating isogenic clones with different copy number profiles for part of the chromosome 1q arm, we observed increased sensitivity to MCL1 and PI3K inhibitors with arm-level gain. Lastly, we demonstrated synergy between MCL1 and PI3K inhibitors and dissected their mechanism of action in MM with 1q+, uncovering a cytostatic effect. In conclusion, this study highlights that MM with 1q+ may present enhanced sensitivity to MCL1 and PI3K inhibitors, enabling their use at lower doses without sacrificing efficacy, and may thus accelerate the development of targeted therapy for patients with MM and 1q+.

Year:

2025

Detection of light chain (LC) monoclonal gammopathies (MGs) traditionally relies on serum free LC (FLC) κ, λ, and their ratio (κ/λ) reference ranges based on a mostly White population. We investigated FLC values in a racially diverse population by screening 10 035 individuals for heavy chain MG, identifying 9028 negative cases whose FLC were measured. Participants included 4149 from the PROMISE study (United States, n = 2383; South Africa, n = 1766) and 4879 from the Mass General Brigham Biobank, with 44% self-identifying as Black. Using standard FLC reference ranges, 1074 of 10 035 individuals (10.7%) were diagnosed with LC monoclonal gammopathy of undetermined significance (MGUS), with 99% being κ-restricted. In the United States, 14.8% of Black and 4% of White individuals were diagnosed (P < .01). Among US participants of African (AFR) and European (EUR) genetic ancestry, 14.4% AFR and 2.9% EUR were diagnosed (P < .01). Among South Africans (100% Black), 27.8% were diagnosed using standard ranges. To avoid overdiagnosis, we propose a new κ/λ ratio reference range (0.686 to 2.10) for populations of AFR descent with normal renal function, with standard values for κ and λ being 7.97 to 77.50 mg/L and 6.20 to 49.20 mg/L, respectively. This reduces LC-MGUS overdiagnosis by 91% (10.7% vs 0.97%). Using the new reference, LC-MGUS accounts for 8.8% of MGUS cases, with 74% being κ-restricted, consistent with LC myeloma rates. These findings highlight the importance of basing disease definitions, such as MGUS, on diverse populations. Adopting our proposed FLC reference values would reduce MGUS overdiagnosis among Black individuals, avoiding unnecessary financial, psychological, and medical consequences. This study includes data from NCT03689595.

Year:

2025

Year:

2025

Early therapeutic intervention in high-risk smoldering multiple myeloma (HR-SMM) has shown benefits, however, no studies have assessed whether biochemical progression or response depth predicts long-term outcomes. The single-arm I-PRISM phase II trial (NCT02916771) evaluated ixazomib, lenalidomide, and dexamethasone in 55 patients with HR-SMM. The primary endpoint, median progression-free survival (PFS), was not reached (NR) (95% CI: 57.7–NR, median follow-up 50 months). The secondary endpoint, biochemical PFS, was 48.6 months (95% CI: 39.9–NR) and coincided with or preceded SLiM-CRAB in eight patients. For additional secondary objectives, the overall response rate was 93% with 31% achieving complete response (CR) and 45% very good partial response (VGPR) or better. CR correlated strongly with the absence of SLiM-CRAB and biochemical progression. MRD-negativity (10 -5 sensitivity) predicted a 5-year biochemical PFS of 100% versus 40% in MRD-positive patients (p = 0.051), demonstrating that deep responses significantly improve time to progression. Exploratory single-cell RNA sequencing linked tumor MHC class I expression to proteasome inhibitor response, and a lower proportion of GZMB+ T cells within clonally expanded CD8+ T cells associated with suboptimal outcomes.

Year:

2025

Year:

2025

Aberrant alterations in genome copy number, chromatin accessibility, and transcriptional programs all play pivotal roles in cancer. The Numbat algorithm has been widely adopted to perform copy number variation (CNV) inference from single-cell RNA sequencing (scRNA-seq) data. Here, we introduce Numbat-multiome that extends the capabilities of Numbat to perform CNV inference from both scRNA-seq and accessible chromatin profiles (through single-cell Assay of Transposase [Tn5]-Accessible Chromatin sequencing [scATAC-seq] data), either separately or in an integrated manner. Our approach unifies data originating from different modalities through a binning strategy that relies on a common genomic coordinate system across modalities. We demonstrate the tool’s robust performance in four running modes (RNA gene, RNA bin, ATAC bin, and Combined bin) using benchmark cohorts of tumors with dynamic changes in expression patterns and copy number heterogeneity, including early-stage multiple myeloma and Richter’s syndrome arising from chronic lymphocytic leukemia, validated against whole-genome sequencing. Numbat-multiome achieves high precision and recall (median F1>0.9) across different CNV event types, with consistent performance across sample types and event lengths. The tool’s ability to track clonal evolution in serial samples and identify rare subclones allows for integration of epigenomic profiles at the subclonal level, providing new insights into the stepwise genetic and epigenetic changes underlying cancer phenotypic shifts.

Year:

2025

Year:

2025

Supplementary data contains additional Materials and Methods used to generate results presented only in the supplementary figures and tables, as well as more detailed bioinformatics methods. Figure S1 shows correlation between clinical measures of disease pathology, survival, and circulating tumor cells enumeration. Figure S2 shows characteristics of isolated circulating tumor cells from peripheral blood of precursor disease patients. Figure S3 shows cohort-level genomic characterization of tumor in MM precursor stages with CTCs. Figure S4 shows longitudinal and tissue-matched genomic characterization of driver mutations. Figure S5 shows comparison of mutational processes between BMPCs and CTCs assigned to most likely PCAWG composite reference signature. Table S1 shows clinical characteristics and sampling of participants in this study. Table S2 shows whole-genome sequencing coverage and library metrics. Table S3 shows clinical BM FISH results and cells recovered for cohort with matched samples. Table S4 shows comparison of BCR sequence between BMPCs and CTCs. Table S5 shows clinical BM FISH results of peripheral blood only cohort and CTCs recovered. Table S6 shows enumeration of single nucleotide variants and short insertions and deletions discovered from WGS of CTCs. Table S7 shows enumeration of structural variants reconstructed from WGS of CTCs.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (32)

Stéphane Minvielle

CNRS Délégation Bretagne et Pays de Loire

FRANCE
View details

Meletios Dimopoulos

Professor

National and Kapodistrian University of Athens

GREECE
View details

Shaji Kumar

Medical College of Wisconsin

UNITED STATES
View details

Kwee Yong

University College London

UNITED KINGDOM
View details

Mansour Poorebrahim

Deutsches Krebsforschungszentrum

GERMANY
View details

Paola Neri

University of Calgary

CANADA
View details

Kirsten Kübler

University Hospital Bonn

GERMANY
View details

Hermann Einsele

University Hospital Würzburg

GERMANY
View details

Brian Walker

Professor

University of Miami

UNITED STATES
View details

María-Victoria Mateos

University Hospital of Salamanca

SPAIN
View details

Russell J.H. Ryan

Associate Professor

University of Michigan Medical School

UNITED STATES
View details

Annie Cowan

Dana-Farber Cancer Institute

UNITED STATES
View details

Luca Pinello

Associate Member

Broad Institute

UNITED STATES
View details

Kendell Clement

Assistant Professor

University of Utah

UNITED STATES
View details

Bachisio Ziccheddu

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details

K. Martin Kortüm

University Hospital Würzburg

GERMANY
View details

Irene Ghobrial

Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Catherine Pellat-Deceunynck

Université de Nantes

FRANCE
View details

Niccolò Bolli

Associate Professor

University of Milan

ITALY
View details

Esther Rheinbay

Massachusetts General Hospital

UNITED STATES
View details

Jesus F. San Miguel

-

SPAIN
View details

Gad Getz

Broad Institute

UNITED STATES
View details

Wenlong Chen

Senior Researcher

University of Witwatersrand

SOUTH AFRICA
View details

Jesse Engreitz

Stanford University

UNITED STATES
View details

Mathieu Lupien

Senior Scientist

University Health Network

CANADA
View details

Tim Coorens

Research Group Leader

European Bioinformatics Institute

UNITED KINGDOM
View details

Sebastian Theurich

Oberarzt, Hämatologie und Onkologie, W2 Professor für Krebs- und Immunmetabolismus

Klinikum der Universität München

GERMANY
View details

Bruno David Lourenço Paiva

Clinica Universidad de Navarra

SPAIN
View details

Stephen Chong

National University of Singapore (NUS)

SINGAPORE
View details

Yoshinobu Konishi

Assistant Professor

Kyoto University Hospital

JAPAN
View details

Marc S. Raab

University Hospital Heidelberg

GERMANY
View details

Michelle Aranha

Computational Scientist

Broad Institute

UNITED STATES
View details